Literature DB >> 1329294

Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine.

M A Moskowitz1.   

Abstract

Sumatriptan and the ergot alkaloids are useful tools for deciphering drug mechanisms in migraine and related headaches. Both neuronal and vascular mechanisms have been proposed on the basis of actions of 5-HT at receptors resembling the 5-HT1D subtype. In this Viewpoint article, Michael A. Moskowitz argues that blockade of neural transmission and the neurogenic inflammatory response provides a mechanism by which sumatriptan and ergot alkaloids alleviate vascular headaches. He postulates, with similar arguments, that sumatriptan and ergot alkaloids may block headaches that develop from meningovascular inflammatory disorders such as from viral and bacterial meningitis and from the sequelae of head injury.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329294     DOI: 10.1016/0165-6147(92)90097-p

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  63 in total

1.  No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.

Authors:  I Bouchelet; B Case; A Olivier; E Hamel
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

2.  Molecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT(1B) receptor.

Authors:  P Bhalla; H S Sharma; X Ma; T Wurch; P J Pauwels; P R Saxena
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

3.  [PET and Doppler sonography in headaches].

Authors:  A May; C Weiller
Journal:  Schmerz       Date:  1996-06-17       Impact factor: 1.107

4.  Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjects.

Authors:  Paul L M Van Giersbergen; Jasper Dingemanse
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jan-Mar       Impact factor: 2.441

5.  The non-peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats.

Authors:  S L Shepheard; D J Williamson; R G Hill; R J Hargreaves
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

6.  Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.

Authors:  B Schaerlinger; P Hickel; N Etienne; L Guesnier; L Maroteaux
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

7.  Effect of a 5-HT1 receptor agonist, CP-122,288, on oedema formation induced by stimulation of the rat saphenous nerve.

Authors:  R Kajekar; P Gupta; N B Shepperson; S D Brain
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

Review 8.  Pharmacological rationale for the clinical use of caffeine.

Authors:  J Sawynok
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 9.  A practical guide to the management and prevention of migraine.

Authors:  H C Diener; H Kaube; V Limmroth
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

10.  Effects of sumatriptan on the cerebral intraparenchymal microcirculation in the cat.

Authors:  M Kobari; Y Fukuuchi; M Tomita; N Tanahashi; S Konno; H Takeda
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.